This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.
West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.
Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for XMHQ
Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.
Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.
Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden
by Zacks Equity Research
Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and Molina (MOH) have performed compared to their sector so far this year.
Humana (HUM) to Support Eligible Medicaid Members in Louisiana
by Zacks Equity Research
Humana (HUM) is picked by the Louisiana Department of Health for a contract win to help serve the Medicaid members in Louisiana.
Ecolab (ECL) Q4 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across most of its segments drives its Q4 sales despite business challenges.
Centene (CNC) Boosts Presence in Louisiana With Contract Win
by Zacks Equity Research
Centene's (CNC) latest contract renewal tends to improve health outcomes of Medicaid members of Louisiana.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina (MOH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPMD
Molina (MOH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
by Zacks Equity Research
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.
Anthem (ANTM) Q4 Earnings Top Estimates
by Zacks Equity Research
Anthem (ANTM) delivered earnings and revenue surprises of 0.59% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?